Share Price and Basic Stock Data
Last Updated: October 18, 2025, 5:48 pm
| PEG Ratio | -1.44 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lyka Labs Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹351 Cr and a share price of ₹98.4. The company reported sales of ₹93 Cr for the fiscal year ending March 2023, which represented a decline from ₹194 Cr in March 2022. However, there was a notable recovery in subsequent quarters, with sales rising to ₹32.56 Cr in December 2023 and further improving to ₹41.16 Cr by September 2024. This trend reflects a potential rebound in demand and operational recovery. The operating profit margin (OPM) stood at 11.14% for the trailing twelve months, which is modest compared to industry standards, indicating room for efficiency improvements. The company’s cash conversion cycle (CCC) is reported at 97 days, suggesting that it takes a considerable time to convert investments in inventory and accounts receivable into cash, which can impact liquidity. Overall, the revenue trajectory shows signs of recovery, yet the company must address its operational efficiencies to enhance profitability.
Profitability and Efficiency Metrics
Lyka Labs Ltd’s profitability metrics illustrate a challenging landscape. The company recorded a net profit of ₹8 Cr for the trailing twelve months, translating to an earnings per share (EPS) of ₹0.26. This is a significant improvement from the net loss of ₹13 Cr reported for the fiscal year ending March 2023. Despite this recovery, the return on equity (ROE) remains relatively low at 9.31%, indicating that shareholder returns are not maximized. The return on capital employed (ROCE) is slightly better at 9.91%, reflecting the company’s ability to generate profits from its capital. The interest coverage ratio (ICR) is reported at 3.51x, suggesting that the company can comfortably cover its interest obligations, which is a positive indicator for investors. However, the operating profit margin has fluctuated, with a notable drop to 7.27% in March 2024, highlighting potential inefficiencies in managing operational costs. The company’s ability to stabilize and improve these metrics will be crucial for its long-term sustainability.
Balance Sheet Strength and Financial Ratios
Lyka Labs Ltd’s balance sheet shows a mixed picture. The company reported total borrowings of ₹39 Cr against reserves of ₹68 Cr, indicating a relatively manageable debt level with a debt-to-equity ratio of 0.84. This suggests that the company is not overly leveraged compared to industry norms. The current ratio stands at 1.35, reflecting adequate short-term liquidity to meet its obligations, while the quick ratio of 1.09 reinforces this liquidity position. However, the book value per share has seen significant fluctuations, recorded at ₹20.63 for March 2024, which is an improvement from previous years. The asset turnover ratio at 0.72% indicates that the company is generating a modest revenue per unit of asset, suggesting inefficiencies in asset utilization. The overall financial ratios indicate that while the company has a sound liquidity position, it must enhance asset utilization and operational efficiency to strengthen its financial health further.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lyka Labs Ltd reveals a stable yet evolving investor base. Promoter holdings stand at 58.16%, reflecting strong control by the founding members, which can instill confidence among investors. Foreign institutional investors (FIIs) hold a meager 0.16%, while domestic institutional investors (DIIs) account for 0.66%. The public shareholding is at 41.02%, indicating a considerable retail investor presence. The number of shareholders has slightly declined to 28,189, which could be a concern for liquidity and market perception. The increasing promoter stake from 47.58% in September 2022 to the current level signals confidence in the company’s prospects. However, the low institutional participation could limit the stock’s visibility and attractiveness to larger investors. Investor confidence largely hinges on the company’s ability to demonstrate consistent performance and operational improvements in the coming quarters.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiencies improve, Lyka Labs Ltd could position itself for a more robust recovery in the pharmaceuticals sector. However, risks such as fluctuating sales trends and the significant cash conversion cycle remain pertinent. The company’s ability to manage costs effectively while enhancing revenue streams will be crucial for long-term sustainability. Furthermore, the low institutional participation poses a risk for liquidity, which could affect stock performance in volatile market conditions. If the company can improve its OPM and return metrics, it may attract more institutional investors, thereby enhancing overall market confidence. Balancing operational efficiency with strategic growth initiatives will be key as Lyka Labs navigates the complexities of the pharmaceutical landscape in India.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lyka Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.49 | 25.53 | 17.82 | 22.24 | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 |
| Expenses | 21.18 | 20.50 | 15.61 | 18.94 | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 |
| Operating Profit | 6.31 | 5.03 | 2.21 | 3.30 | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 |
| OPM % | 22.95% | 19.70% | 12.40% | 14.84% | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% |
| Other Income | 0.95 | 0.98 | -5.95 | 0.02 | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 |
| Interest | 2.91 | 3.03 | 3.08 | 2.85 | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 |
| Depreciation | 3.59 | 3.62 | 3.47 | 3.47 | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 |
| Profit before tax | 0.76 | -0.64 | -10.29 | -3.00 | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 |
| Tax % | 6.58% | -46.88% | 2.24% | 0.00% | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% |
| Net Profit | 0.60 | -0.38 | -10.42 | -3.01 | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 2.10 | 2.70 | 2.03 | 0.99 |
| EPS in Rs | 0.21 | -0.13 | -3.63 | -0.98 | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 |
Last Updated: August 1, 2025, 5:50 pm
Below is a detailed analysis of the quarterly data for Lyka Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 33.03 Cr.. The value appears to be declining and may need further review. It has decreased from 33.43 Cr. (Mar 2025) to 33.03 Cr., marking a decrease of 0.40 Cr..
- For Expenses, as of Jun 2025, the value is 29.35 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.35 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.68 Cr.. The value appears to be declining and may need further review. It has decreased from 4.08 Cr. (Mar 2025) to 3.68 Cr., marking a decrease of 0.40 Cr..
- For OPM %, as of Jun 2025, the value is 11.14%. The value appears to be declining and may need further review. It has decreased from 12.20% (Mar 2025) to 11.14%, marking a decrease of 1.06%.
- For Other Income, as of Jun 2025, the value is 0.63 Cr.. The value appears to be declining and may need further review. It has decreased from 0.82 Cr. (Mar 2025) to 0.63 Cr., marking a decrease of 0.19 Cr..
- For Interest, as of Jun 2025, the value is 0.85 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.47 Cr. (Mar 2025) to 0.85 Cr., marking an increase of 0.38 Cr..
- For Depreciation, as of Jun 2025, the value is 2.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.42 Cr. (Mar 2025) to 2.11 Cr., marking an increase of 0.69 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.35 Cr.. The value appears to be declining and may need further review. It has decreased from 3.01 Cr. (Mar 2025) to 1.35 Cr., marking a decrease of 1.66 Cr..
- For Tax %, as of Jun 2025, the value is 26.67%. The value appears to be improving (decreasing) as expected. It has decreased from 32.89% (Mar 2025) to 26.67%, marking a decrease of 6.22%.
- For Net Profit, as of Jun 2025, the value is 0.99 Cr.. The value appears to be declining and may need further review. It has decreased from 2.03 Cr. (Mar 2025) to 0.99 Cr., marking a decrease of 1.04 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.26. The value appears to be declining and may need further review. It has decreased from 0.50 (Mar 2025) to 0.26, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 141 |
| Expenses | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 124 |
| Operating Profit | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | 18 |
| OPM % | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% | 13% |
| Other Income | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 2 |
| Interest | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 2 |
| Depreciation | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 7 |
| Profit before tax | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | 11 |
| Tax % | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | |
| Net Profit | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | 8 |
| EPS in Rs | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | 2.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -171.43% | 68.42% | -950.00% | 84.13% | 480.00% | -134.21% | 76.92% | 366.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 239.85% | -1018.42% | 1034.13% | 395.87% | -614.21% | 211.13% | 289.74% |
Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 18% |
| 3 Years: | -11% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 18% |
| 3 Years: | -43% |
| TTM: | 681% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 39% |
| 3 Years: | -13% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: July 25, 2025, 2:50 pm
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
| Reserves | 30 | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 68 |
| Borrowings | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 |
| Other Liabilities | 113 | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 33 |
| Total Liabilities | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
| Fixed Assets | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 |
| CWIP | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 |
| Total Assets | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
Below is a detailed analysis of the balance sheet data for Lyka Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2024) to 36.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 59.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 20.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 33.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 176.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 85.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2024) to 85.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 22.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Mar 2024) to 90.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 176.00 Cr.. The value appears strong and on an upward trend. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..
Notably, the Reserves (68.00 Cr.) exceed the Borrowings (39.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.00 | -109.00 | 20.00 | -103.00 | -117.00 | -98.00 | -145.00 | -143.00 | -29.00 | -58.00 | -43.00 | -21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 |
| Inventory Days | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 |
| Days Payable | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 |
| Cash Conversion Cycle | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 |
| Working Capital Days | -309 | -220 | -242 | -357 | -735 | -265 | -242 | -118 | -121 | -0 | 23 | 51 |
| ROCE % | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Diluted EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Cash EPS (Rs.) | 4.12 | 3.08 | 0.32 | 19.45 | -0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Revenue From Operations / Share (Rs.) | 38.81 | 33.60 | 30.33 | 67.65 | 30.06 |
| PBDIT / Share (Rs.) | 5.65 | 5.19 | 6.59 | 35.99 | 7.41 |
| PBIT / Share (Rs.) | 3.75 | 1.32 | 1.99 | 29.94 | 4.50 |
| PBT / Share (Rs.) | 3.12 | -0.28 | -4.29 | 20.65 | -4.93 |
| Net Profit / Share (Rs.) | 2.22 | -0.79 | -4.29 | 13.40 | -3.52 |
| NP After MI And SOA / Share (Rs.) | 2.24 | -0.75 | -4.30 | 13.59 | -4.03 |
| PBDIT Margin (%) | 14.56 | 15.44 | 21.74 | 53.19 | 24.63 |
| PBIT Margin (%) | 9.67 | 3.92 | 6.54 | 44.25 | 14.98 |
| PBT Margin (%) | 8.03 | -0.83 | -14.15 | 30.52 | -16.39 |
| Net Profit Margin (%) | 5.72 | -2.35 | -14.13 | 19.80 | -11.69 |
| NP After MI And SOA Margin (%) | 5.78 | -2.23 | -14.19 | 20.09 | -13.39 |
| Return on Networth / Equity (%) | 7.73 | -3.65 | -29.07 | 292.38 | 0.00 |
| Return on Capital Employeed (%) | 10.33 | 3.66 | 5.12 | 99.57 | 9.17 |
| Return On Assets (%) | 4.54 | -1.58 | -8.71 | 21.01 | -6.08 |
| Long Term Debt / Equity (X) | 0.17 | 0.61 | 1.38 | 4.63 | -5.84 |
| Total Debt / Equity (X) | 0.35 | 0.81 | 1.55 | 9.66 | -6.24 |
| Asset Turnover Ratio (%) | 0.83 | 0.72 | 0.55 | 0.82 | 0.30 |
| Current Ratio (X) | 1.45 | 1.35 | 1.36 | 0.52 | 0.59 |
| Quick Ratio (X) | 1.18 | 1.09 | 1.14 | 0.44 | 0.50 |
| Inventory Turnover Ratio (X) | 12.12 | 12.72 | 3.05 | 4.31 | 2.23 |
| Interest Coverage Ratio (X) | 8.87 | 3.51 | 1.71 | 5.13 | 0.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.49 | 0.54 | 0.51 | 3.23 | 0.65 |
| Enterprise Value (Cr.) | 396.90 | 401.32 | 381.55 | 501.74 | 229.87 |
| EV / Net Operating Revenue (X) | 2.87 | 3.61 | 4.10 | 2.59 | 2.67 |
| EV / EBITDA (X) | 19.68 | 23.37 | 18.85 | 4.86 | 10.82 |
| MarketCap / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| Price / BV (X) | 3.48 | 5.14 | 7.07 | 29.17 | -2.89 |
| Price / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| EarningsYield | 0.02 | -0.01 | -0.04 | 0.10 | -0.15 |
After reviewing the key financial ratios for Lyka Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.12. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 4.12, marking an increase of 1.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 38.81. It has increased from 33.60 (Mar 24) to 38.81, marking an increase of 5.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 5.19 (Mar 24) to 5.65, marking an increase of 0.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.75. This value is within the healthy range. It has increased from 1.32 (Mar 24) to 3.75, marking an increase of 2.43.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.12. This value is within the healthy range. It has increased from -0.28 (Mar 24) to 3.12, marking an increase of 3.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.22. This value is within the healthy range. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.24. This value is within the healthy range. It has increased from -0.75 (Mar 24) to 2.24, marking an increase of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 14.56. This value is within the healthy range. It has decreased from 15.44 (Mar 24) to 14.56, marking a decrease of 0.88.
- For PBIT Margin (%), as of Mar 25, the value is 9.67. This value is below the healthy minimum of 10. It has increased from 3.92 (Mar 24) to 9.67, marking an increase of 5.75.
- For PBT Margin (%), as of Mar 25, the value is 8.03. This value is below the healthy minimum of 10. It has increased from -0.83 (Mar 24) to 8.03, marking an increase of 8.86.
- For Net Profit Margin (%), as of Mar 25, the value is 5.72. This value is within the healthy range. It has increased from -2.35 (Mar 24) to 5.72, marking an increase of 8.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.78. This value is below the healthy minimum of 8. It has increased from -2.23 (Mar 24) to 5.78, marking an increase of 8.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.73. This value is below the healthy minimum of 15. It has increased from -3.65 (Mar 24) to 7.73, marking an increase of 11.38.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 10.33, marking an increase of 6.67.
- For Return On Assets (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 24) to 4.54, marking an increase of 6.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 0.2. It has decreased from 0.61 (Mar 24) to 0.17, marking a decrease of 0.44.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.35, marking a decrease of 0.46.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.72 (Mar 24) to 0.83, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.45, marking an increase of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.18, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.12. This value exceeds the healthy maximum of 8. It has decreased from 12.72 (Mar 24) to 12.12, marking a decrease of 0.60.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.87. This value is within the healthy range. It has increased from 3.51 (Mar 24) to 8.87, marking an increase of 5.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.49. This value is within the healthy range. It has increased from 0.54 (Mar 24) to 4.49, marking an increase of 3.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 396.90. It has decreased from 401.32 (Mar 24) to 396.90, marking a decrease of 4.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.61 (Mar 24) to 2.87, marking a decrease of 0.74.
- For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has decreased from 23.37 (Mar 24) to 19.68, marking a decrease of 3.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 25, the value is 3.48. This value exceeds the healthy maximum of 3. It has decreased from 5.14 (Mar 24) to 3.48, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
- Net Profit Margin: 5.72%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.73% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 44.9 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.72%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 4801/B & 4802/A, Ankleshwar Gujarat 393002 | companysecretary@lykalabs.com. http://www.lykalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Babulal Jain | Chairman |
| Mr. Kunal Gandhi | Managing Director & CEO |
| Mr. Yogesh B Shah | WholeTime Director & CFO |
| Mr. Shashil Mendosa | Non Executive Director |
| Mr. Prashant Godha | Non Executive Director |
| Mrs. Dhara Shah | Independent Director |
| Mr. Neeraj Golas | Independent Director |
| Ms. Archana S Yadav | Independent Director |
FAQ
What is the intrinsic value of Lyka Labs Ltd?
Lyka Labs Ltd's intrinsic value (as of 19 October 2025) is 98.92 which is 4.79% higher the current market price of 94.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 337 Cr. market cap, FY2025-2026 high/low of 177/90.2, reserves of ₹68 Cr, and liabilities of 176 Cr.
What is the Market Cap of Lyka Labs Ltd?
The Market Cap of Lyka Labs Ltd is 337 Cr..
What is the current Stock Price of Lyka Labs Ltd as on 19 October 2025?
The current stock price of Lyka Labs Ltd as on 19 October 2025 is 94.4.
What is the High / Low of Lyka Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lyka Labs Ltd stocks is 177/90.2.
What is the Stock P/E of Lyka Labs Ltd?
The Stock P/E of Lyka Labs Ltd is 44.9.
What is the Book Value of Lyka Labs Ltd?
The Book Value of Lyka Labs Ltd is 29.0.
What is the Dividend Yield of Lyka Labs Ltd?
The Dividend Yield of Lyka Labs Ltd is 0.00 %.
What is the ROCE of Lyka Labs Ltd?
The ROCE of Lyka Labs Ltd is 9.91 %.
What is the ROE of Lyka Labs Ltd?
The ROE of Lyka Labs Ltd is 9.31 %.
What is the Face Value of Lyka Labs Ltd?
The Face Value of Lyka Labs Ltd is 10.0.